Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy

References

• Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–423. doi:10.3322/caac.21631
   PubMed Web of Science ®Google Scholar
• Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324(19):1980–1991. doi:10.1001/jama.2020.17598
   PubMed Web of Science ®Google Scholar
• Ravi P, Pond GR, Diamantopoulos LN, et al. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int. 2021;128(5):607–614. doi:10.1111/bju.15434
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Franco A, Simone G, et al. Validation of the COBRA nomogram for the prediction of cancer specific survival in patients treated with radical cystectomy for bladder cancer: an international wide cohort study. Eur J Surg Oncol. 2021;47(10):2646–2650. doi:10.1016/j.ejso.2021.04.035
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi:10.1016/j.eururo.2016.06.010
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61:1229–1238. doi:10.1016/j.eururo.2011.12.010
   PubMed Web of Science ®Google Scholar
• Schuettfort VM, Pradere B, D’Andrea D, et al. Prognostic impact of preoperative plasma levels of urokinase plasminogen activator proteins on disease outcomes after radical cystectomy. J Urol. 2021;206(5):1122–1131. doi:10.1097/JU.0000000000001936
   PubMed Web of Science ®Google Scholar
• Laukhtina E, Schuettfort VM, D’Andrea D, et al. Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Mol Carcinog. 2022;61(1):5–18. doi:10.1002/mc.23355
   PubMed Web of Science ®Google Scholar
• Christensen E, Birkenkamp-Demtröder K, Nordentoft I, et al. Liquid Biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71(6):961–969. doi:10.1016/j.eururo.2016.12.016
   PubMed Web of Science ®Google Scholar
• Amara CS, Vantaku V, Lotan Y, Putluri N. Recent advances in the metabolomic study of bladder cancer. Expert Rev Proteomics. 2019;16(4):315–324. doi:10.1080/14789450.2019.1583105
   PubMed Web of Science ®Google Scholar
• Liu X, Cheng X, Liu X, et al. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery. Int J Cancer. 2018;143(2):408–418. doi:10.1002/ijc.31323
   PubMed Web of Science ®Google Scholar
• Lane LA, Qian X, Nie S. SERS nanoparticles in Medicine: from label free detection to spectroscopic tagging. Chem Rev. 2015;115(19):10489–10529. doi:10.1021/acs.chemrev.5b00265
   PubMed Web of Science ®Google Scholar
• Tahir MA, Dina NE, Cheng H, Valev VK, Zhang L. Surface-enhanced Raman spectroscopy for bioanalysis and diagnosis. Nanoscale. 2021;13(27):11593–11634. doi:10.1039/D1NR00708D
   PubMed Web of Science ®Google Scholar
• Chen N, Rong M, Shao X, et al. Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL. Int J Nano Med. 2017;12:5399–5407. doi:10.2147/IJN.S137756
   PubMed Web of Science ®Google Scholar
• Nargis HF, Nawaz H, Bhatti HN, Jilani K, Saleem M. Comparison of surface enhanced Raman spectroscopy and Raman spectroscopy for the detection of breast cancer based on serum samples. Spectrochim Acta A Mol Biomol Spectrosc. 2021;246:119034. doi:10.1016/j.saa.2020.119034
   PubMed Web of Science ®Google Scholar
• Lei J, Yang D, Li R, et al. Label-free surface-enhanced Raman spectroscopy for diagnosis and analysis of serum samples with different types lung cancer. Spectrochim Acta A Mol Biomol Spectrosc. 2021;261:120021. doi:10.1016/j.saa.2021.120021
   PubMed Web of Science ®Google Scholar
• Shao X, Zhang H, Wang Y, et al. Deep convolutional neural networks combine Raman spectral signature of serum for prostate cancer bone metastases screening. Nanomedicine. 2020;29:102245. doi:10.1016/j.nano.2020.102245
   PubMed Web of Science ®Google Scholar
• Morselli S, Baria E, Cicchi R, et al. The feasibility of multimodal fiber optic spectroscopy analysis in bladder cancer detection, grading, and staging. Urologia. 2021;88(4):306–314. doi:10.1177/03915603211007018
   PubMed Web of Science ®Google Scholar
• Baria E, Morselli S, Anand S, et al. Label-free grading and staging of urothelial carcinoma through multimodal fibre-probe spectroscopy. J Biophotonics. 2019;12(11):e201900087. doi:10.1002/jbio.201900087
   PubMed Web of Science ®Google Scholar
• Hu D, Xu X, Zhao Z, et al. Detecting urine metabolites of bladder cancer by surface-enhanced Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2021;247:119108. doi:10.1016/j.saa.2020.119108
   PubMed Web of Science ®Google Scholar
• Chen S, Zhu S, Cui X, et al. Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy. Biomed Opt Express. 2019;10(7):3533–3544. doi:10.1364/BOE.10.003533
   PubMed Web of Science ®Google Scholar
• Shapiro A, Gofrit ON, Pizov G, Cohen JK, Maier J. Raman molecular imaging: a novel spectroscopic technique for diagnosis of bladder cancer in urine specimens. Eur Urol. 2011;59(1):106–112. doi:10.1016/j.eururo.2010.10.027
   PubMed Web of Science ®Google Scholar
• Lee PC, Meisel DJJ. Adsorption and surface-enhanced Raman of dyes on silver and gold sols. J Phys Chem. 1982;86(17):3391–3395. doi:10.1021/j100214a025
   Web of Science ®Google Scholar
• Pan J, Shao X, Zhu Y, et al. Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S. Int J Nanomedicine. 2019;14:431–440. doi:10.2147/IJN.S186226
   PubMed Web of Science ®Google Scholar
• Malini R, Venkatakrishna K, Kurien J, et al. Discrimination of normal, inflammatory, premalignant, and malignant oral tissue: a Raman spectroscopy study. Biopolymers. 2006;81(3):179–193. doi:10.1002/bip.20398
   PubMed Web of Science ®Google Scholar
• Cheng WT, Liu MT, Liu HN, Lin SY. Micro-Raman spectroscopy used to identify and grade human skin pilomatrixoma. Microsc Res Tech. 2005;68(2):75–79. doi:10.1002/jemt.20229
   PubMed Web of Science ®Google Scholar
• Ruiz-Chica AJ, Medina MA, Sánchez-Jiménez F, Ramírez FJ. Characterization by Raman spectroscopy of conformational changes on guanine–cytosine and adenine–thymine oligonucleotides induced by aminooxy analogues of spermidine. J Raman Spectrosc. 2004;35:93–100. doi:10.1002/jrs.1107
   Web of Science ®Google Scholar
• Patel KM, van der Vos KE, Smith CG, et al. Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer. Sci Rep. 2017;7(1):5554. doi:10.1038/s41598-017-05623-3
   PubMed Web of Science ®Google Scholar
• Schlücker S. Surface-enhanced Raman spectroscopy: concepts and chemical applications. Angew Chem Int Ed Engl. 2014;53(19):4756–4795. doi:10.1002/anie.201205748
   PubMed Web of Science ®Google Scholar
• Qian H, Shao X, Zhu Y, et al. Surface-enhanced Raman spectroscopy of preoperative serum samples predicts Gleason grade group upgrade in biopsy Gleason grade group 1 prostate cancer. Urol Oncol. 2020;38(6):601.e1–601.e9. doi:10.1016/j.urolonc.2020.02.009
   PubMed Web of Science ®Google Scholar
• Feng S, Chen R, Lin J, et al. Gastric cancer detection based on blood plasma surface-enhanced Raman spectroscopy excited by polarized laser light. Biosens Bioelectron. 2011;26(7):3167–3174. doi:10.1016/j.bios.2010.12.020
   PubMed Web of Science ®Google Scholar
• Xiao R, Zhang X, Rong Z, et al. Non-invasive detection of hepatocellular carcinoma serum metabolic profile through surface-enhanced Raman spectroscopy. Nanomedicine. 2016;12(8):2475–2484. doi:10.1016/j.nano.2016.07.014
   PubMed Web of Science ®Google Scholar
• Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37(18):1547–1557. doi:10.1200/JCO.18.02052
   PubMed Web of Science ®Google Scholar
• Vandekerkhove G, Todenhöfer T, Annala M, et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin Cancer Res. 2017;23(21):6487–6497. doi:10.1158/1078-0432.CCR-17-1140
   PubMed Web of Science ®Google Scholar
• Romas NA, Ionascu L, Sholem S, Ionescu G, Veenema RJ. A new method for determination of urinary tryptophan metabolites in bladder carcinoma. J Urol. 1975;114(2):223–225. doi:10.1016/S0022-5347(17)66991-X
   PubMed Web of Science ®Google Scholar
• Yoshida O, Brown RR, Bryan GT. Relationship between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors. Cancer. 1970;25(4):773–780. doi:10.1002/1097-0142(197004)25:4<773::AID-CNCR2820250405>3.0.CO;2-X
   PubMed Web of Science ®Google Scholar
• Lee SH, Mahendran R, Tham SM, et al. Tryptophan-kynurenine ratio as a biomarker of bladder cancer. BJU Int. 2021;127(4):445–453. doi:10.1111/bju.15205
   PubMed Web of Science ®Google Scholar
• Li C, Zhao H. Tryptophan and its metabolites in lung cancer: basic functions and clinical significance. Front Oncol. 2021;11:707277. doi:10.3389/fonc.2021.707277
   PubMed Web of Science ®Google Scholar
• Miyagi Y, Higashiyama M, Gochi A, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011;6:e24143. doi:10.1371/journal.pone.0024143
   PubMed Web of Science ®Google Scholar